Related Experiment Videos
HTLV-I-associated myelopathy manifested after renal transplantation.
Y Nakatsuji1, F Sugai, S Watanabe
1Department of Neurology, Osaka University Graduate School of Medicine, Yamada-oka 2-2, Suita, 565-0871, Osaka, Japan. yuji@neurol.med.osaka-u.ac.jp
Journal of the Neurological Sciences
|September 12, 2000
Summary
A kidney transplant recipient developed Human T-lymphotropic virus type I-associated myelopathy (HAM) years after the procedure. This suggests infection transmission via the transplanted organ, with immunosuppressants showing limited efficacy against HAM/TSP.
Area of Science:
- Neurology
- Infectious Diseases
- Transplantation Immunology
Background:
- Human T-lymphotropic virus type I (HTLV-I) infection can lead to HTLV-I-associated myelopathy (HAM), also known as tropical spastic paraparesis (TSP).
- Renal transplantation involves the transfer of organs between individuals, potentially transmitting infectious agents.
- Immunosuppressive therapy is crucial post-transplantation to prevent organ rejection.
Observation:
- A patient, initially seronegative for HTLV-I, developed HAM symptoms four years after receiving a cadaveric renal transplant.
- The patient was treated with standard immunosuppressive agents: cyclosporin A (CsA), mycophenolate mofetil (MMF), and prednisolone (PSL).
Findings:
- The case suggests that HTLV-I infection was transmitted through the transplanted kidney.
- The immunosuppressive regimen (CsA, MMF, PSL) appeared to be ineffective in preventing the onset or progression of HAM/TSP.
Implications:
- This case highlights the risk of HTLV-I transmission via organ transplantation.
- Current immunosuppressive strategies may not adequately control HTLV-I-associated neurological diseases post-transplant.
- Further research is needed to explore preventative measures and alternative treatments for HAM/TSP in transplant recipients.